Peter Bely on the directions of development of innovative drug therapy in Russia

According to the Ministry of Industry and Trade, the Industry Development Fund has formed an investment portfolio of 50 billion rubles to support innovations in the Russian pharmaceutical industry. At SPIEF 2022, experts and government representatives announced current proposals for government support for the industry. 

In an interview with RBC, Peter Bely, Chairman of the Board of Directors of Promomed Group, outlined areas for the development of innovative drug therapy in Russia.

What are the main directions for the development of innovative drug therapy in our country, and what specific steps are needed to implement this concept?

Peter Bely: Two and a half years ago, we faced the global threat of covid, and I must say that the Russian Government, the regulatory mechanism, and the industry's willingness to provide solutions to combat covid have produced tremendous results. We have developed a whole series of innovative drugs in different therapeutic groups. As a country, we are one of the champions in creating vaccines. This has shown Russia's great willingness to become a source of innovative solutions for the treatment of the most critical diseases that pose the greatest threat.

First. We need a very powerful system for protecting the intellectual property of Russian innovations. Which would start with the first steps, from the creation of a new drug idea to its successful operation on the market.

Second. We need to create a regulatory mechanism that would allow Russian developments in recognized therapeutic classes to enter the market quickly, but without reducing the volume of clinical trials or reducing quality expertise.

The third. It is very important that markets for these drugs are created and they quickly enter the healthcare system.

In the coming months, we will open a giant production of active pharmaceutical substances. 150 items, seven workshops, three workshops dedicated to oncological substances. But it's not our individual efforts that are important, but the fact that so many members of our industry are doing the same thing. And in the relatively short term, we will see a greater sufficiency of domestic substances for the production of our medicines.

How has the St. Petersburg International Economic Forum become for you this year?

Peter the White: We have signed a large comprehensive agreement with the Skolkovo Foundation. We have signed an agreement on cooperation and the opening of joint training and research activities in the field of pharmaceutical technologies with my home university, Moscow State Medical and Dental University. Evdokimova. We have signed a large agreement with the Russian University of Chemical Technology. Mendeleev's. We have expanded the agreement with the Mordovian State University named after Ogareva.

Source: tv.rbc.ru

Sources

1. https://tv.rbc.ru/archive/rbkplus/62ade23e2ae596662ee13146